Evidence map›Paper›PMID 42154043›Full record

ArticleWorld journal of urology2026

Patterns of adjuvant intracavitary instillation and recurrence after endoscopic management of upper tract urothelial carcinoma.

Philipp Korn, Maximilian Pallauf, Jaime O Herrera-Caceres, Soum Lokeshwar, Mark Essien, Alexander Small, Dima Raskolnikov, Nir Kleinmann, Asaf Shvero, Surena F Matin and 15 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Philipp KornDepartment of Urology and Oncology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street / Park 213, MD, 21287, Baltimore, USA.
Maximilian PallaufDepartment of Urology and Oncology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street / Park 213, MD, 21287, Baltimore, USA.
Jaime O Herrera-CaceresDepartment of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Soum LokeshwarDepartment of Urology and Oncology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street / Park 213, MD, 21287, Baltimore, USA.
Mark EssienDepartment of Urology and Oncology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street / Park 213, MD, 21287, Baltimore, USA.
Alexander SmallMontefiore Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Dima RaskolnikovMontefiore Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Nir KleinmannDepartment of Urology, Sheba Medical Center, Ramat Gan, Israel.
Asaf ShveroDepartment of Urology, Sheba Medical Center, Ramat Gan, Israel.
Surena F MatinDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Craig LabbateDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hristos KaimakliotisDepartment of Urology, Indiana University Medical Center, Indianapolis, IN, USA.
Isamu TachibanaDepartment of Urology, Indiana University Medical Center, Indianapolis, IN, USA.
Jennifer LinehanDepartment of Urology, Providence Specialty Medical Group, Santa Monica, CA, USA.
Jane ChoeDepartment of Urology, Providence Specialty Medical Group, Santa Monica, CA, USA.
Ojas ShahDepartment of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Miyad MovassaghiDepartment of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
William HuangDepartment of Urology, New York University Grossman School of Medicine, New York, NY, USA.
Jesse PersilyDepartment of Urology, New York University Grossman School of Medicine, New York, NY, USA.
Aaron PerecmanDepartment of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA.
David CanesDepartment of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA.
Rodrigo R PessoaDepartment of Urology, Moffitt Cancer Center, Tampa, FL, USA.
Aaron PotretzkeDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Jay D RamanDepartment of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Nirmish SinglaDepartment of Urology and Oncology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street / Park 213, MD, 21287, Baltimore, USA. nsingla2@jhmi.edu.

Funding

Deutsche Forschungsgemeinschaft 571588707Paracelsus Medizinische Privatuniversität 2022-FIRE-004-Pallauf
6 · The paper itself

Abstract

main purposeEndoscopic management offers acceptable oncologic control in select patients with upper tract urothelial carcinoma (UTUC) while preserving renal function. Adjuvant intracavitary treatment with chemotherapy or Bacillus Calmette-Guérin (BCG) has been proposed to reduce recurrence risk. We aimed to evaluate the impact of adjuvant intracavitary treatment on ipsilateral UTUC recurrence following endoscopic management. MATERIALS AND

methodsWe queried a multi-institutional cohort of patients who underwent endoscopic management for UTUC. Treatment groups were defined as no instillation, single post-operative instillation, or multiple instillations. Ipsilateral UTUC recurrence-free survival (RFS) was estimated using Kaplan-Meier curves and Cox proportional hazards models evaluated factors associated with recurrence.

resultsA total of 599 renal units, of which 43 received single instillation and 86 multiple instillations, in 334 patients treated endoscopically for UTUC were analyzed. The median follow-up time for patients without recurrence was 12 months (IQR 4-33). Multiple adjuvant instillations of any intracavitary treatment were associated with a significantly improved RFS (HR 0.52, 95% CI 0.34-0.79), whereas a single instillation was not associated with a significant reduction in recurrence (HR 0.64, 95% CI 0.37-1.13). This association between multiple instillations and improved RFS remained significant after adjustment for clinical risk factors, including tumor grade (adjusted HR 0.36, 95% CI 0.16-0.81), and was confirmed in sensitivity analyses limited to patients with primary UTUC (HR 0.46, 95% CI 0.26-0.85).

conclusionMultiple intracavitary instillations of BCG or chemotherapy after endoscopic management of UTUC were associated with longer ipsilateral RFS. These findings suggest a potential benefit of repeated instillations and warrant prospective validation.

Indexed as

Adjuvants, ImmunologicBCG VaccineCarcinoma, Transitional CellUreteral NeoplasmsAdministration, IntravesicalAgedChemotherapy, AdjuvantDeoxycytidineDisease-Free SurvivalFemaleHumansKidneyMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalAdjuvants, ImmunologicBCG VaccineDeoxycytidineMitomycinBCGEndoluminal treatmentEndoscopic managementGemcitabineIntracavitary treatmentMitomycin CUpper tract urothelial carcinoma

Identifiers

PMID42154043

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.